Form 8-K SENOMYX INC For: Jan 22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

�

Form�8-K

�

Current Report Pursuant
to Section�13 or 15(d)�of
The Securities Exchange Act of 1934

�

Date of Report (Date of earliest event reported): January 22, 2015

�

�

Senomyx,�Inc.

(Exact name of registrant as specified in its charter)

�

Delaware (State or other jurisdiction of incorporation)

000-50791 (Commission File Number)

33-0843840 (I.R.S. Employer Identification No.)

�

4767 Nexus Centre�Drive San Diego, California (Address of principal executive offices)

92121 (Zip Code)

�

Registrant's telephone number, including area code:�(858)�646-8300

�

Not Applicable.
(Former name or former address, if changed since last report.)

�

Check the appropriate box below if the Form�8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

�

��� Written communications pursuant to Rule�425 under the Securities Act (17 CFR 230.425)

�

��� Soliciting material pursuant to Rule�14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

��� Pre-commencement communications pursuant to Rule�14d-2(b)�under the Exchange Act (17 CFR 240.14d-2(b))

�

��� Pre-commencement communications pursuant to Rule�13e-4(c)�under the Exchange Act (17 CFR 240.13e-4(c))

�

�

Item 2.05 Costs Associated with Exit or Disposal Activities.

�

On January 22, 2015, Senomyx, Inc. (the "Company") implemented a restructuring plan (the Plan) designed to improve operating efficiencies. Under the Plan, the Company expects to reduce the Companys work force by approximately14 percent, or 16 full-time equivalent employees. The Company expects to substantially complete the Plan in the first quarter of 2015.

�

In connection with the Plan, the Company will focus its research and development efforts on sweet taste modifiers, natural high intensity sweeteners, and flavors improving the taste of reduced salt products. The Company will continue to invest in its commercialization initiatives including direct sales and activities supporting its collaborators commercialization of the Companys flavor ingredients.

�

Under the Plan, with the resulting staff and other expense reductions, the Company expects to reduce its expenses by approximately $2.5 million, net of severance and other costs, for the balance of 2015 and approximately $3.5 million on an annualized basis, thereafter.

�

The Company is offering severance benefits to the affected employees, including cash severance payments, outplacement services and payment of COBRA health care coverage for specified periods. In addition, the Company has offered to accelerate the vesting of specified stock options. Each affected employees eligibility for the severance benefits is contingent upon such employees execution of a separation agreement, which includes a general release of claims against the Company.

�

The Company expects to record restructuring-related expenses in 2015 totaling approximately $440,000 related to termination benefit costs and other costs associated with the workforce reduction. Approximately $400,000 of these expenses are expected to represent cash expenditures, most of which will be expensed and paid in the first quarter of 2015. The remaining approximately $40,000 are one-time, non-cash, stock-based compensation expenses and are expected to be expensed in the first quarter of 2015.

�

The Company ended 2014 with $28.7 million in cash and investments. The Companys collaborators have committed to $21.3 million in development funding payments scheduled to be paid between January 2015 and May 2016. The Company does not have plans to raise money through the issuance of equity or debt to fund the current scope of its operations. ���

�

The above estimated costs and charges may vary materially based on various factors, including those discussed below under the heading Forward-Looking Statements.

�

�

Forward-Looking Statements

�

Information contained in this Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve known and unknown risks and uncertainties. Any statements that are not of historical facts may be deemed to be forward-looking statements, including statements regarding the Companys anticipated workforce reduction, anticipated reduction in expenses, restructuring charges, financial performance, research, development and business prospects and plans, and similar matters. Any such statement may be influenced by a variety of factors, many of which are beyond the control of the Company, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied herein due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: possible changes in the size and components of the expected costs and charges associated with the plan; and risks associated with the Companys ability to achieve the benefits of the planned workforce reduction. All information set forth herein is current as of the date of this Current Report on Form 8-K. The Company is not under any duty to update any of the information herein. For further information regarding risks and uncertainties associated with the Companys business, please refer to the Risk Factors section of the Companys filings with the Securities and Exchange Commission, including, but not limited to, its latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

�

�

�

SIGNATURE

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

�

�	SENOMYX, INC.
�	�	�
�	By:	/S/ ANTONY ROGERS
�	�	Antony Rogers
�	�	Senior Vice�President and Chief Financial Officer
�	�	�
Date: January 22, 2015	�	�

�

�

�

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• INNMI Peptide Continues to Expand Peptide Product Portfolio, Strengthening Global Market Reach and Production Service Capabilities
• LifeOS by Venturis 13 Enters Its Global Scale Phase, Powered by the Team Behind Its AI Operating System
• Argentine Digital Artist Hernán Simó Expands International Presence With Upcoming Monaco, Barcelona and Paris Appearances